Tuesday, 17 September 2019

Ono Pharma, twoXAR announce drug discovery research collaboration

19 March 2019 | News

twoXAR will use its proprietary AI technology to identify a set of lead compounds which demonstrate a novel mechanism of action and will be further optimized by Ono for potential drug candidates

image credit- aimed.io

image credit- aimed.io

Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., a US based artificial intelligence (AI)-driven biopharmaceutical company, have announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.

Under the agreement, twoXAR will use its proprietary AI technology to identify a set of lead compounds which demonstrate a novel mechanism of action and will be further optimized by Ono for potential drug candidates. twoXAR will also predict a set of hypotheses which suggest the efficacy and safety of such lead compounds for the therapy.

twoXAR and Ono will select several compounds with their hypotheses from this set to test in further validation studies. Ono will retain exclusive rights to develop and commercialize the compounds obtained through this collaboration throughout the world, and in return, twoXAR will receive research and license fees from Ono as well as development and sales milestones.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls